NCT01695746View on ClinicalTrials.gov

An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia

CompletedOBSERVATIONAL
Enrollment

108

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Anemia
Interventions
DRUG

C.E.R.A.

Participants receiving 0.6 mcg/kg of C.E.R.A. once every two weeks for correction of anemia and conversion to C.E.R.A. dose 120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks for maintenance of Hb according to local clinical practice or prescribing information will be observed.

Trial Locations (6)

390005

Vadodara

400012

Mumbai

400036

Mumbai

632006

Vellore

751021

Bhubaneswar

500 029

Hyderabad

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01695746 - An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia | Biotech Hunter | Biotech Hunter